DA
PHAT icon

Denali Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Denali Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,500
Closed -$34K – 408
2022
Q1 		$34K Hold
2,500
– – 0.01% 283
2021
Q4 		$49K Buy
+2,500
New +$58.8K 0.02% 251

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Denali Advisors's PHAT Position: Q2 2022 in Review

Denali Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q2 2022, closing a stake of 2,500 shares — an estimated $34K sold.

Denali Advisors first reported a position in PHAT in Q4 2021 and held it in 2 quarters. The position peaked at $49K in Q4 2021. 94 funds tracked by Wall St. Rank hold PHAT as of Q2 2022.

  • Denali Advisors reported no remaining Phathom Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Denali Advisors sold 2,500 Phathom Pharmaceuticals shares in Q2 2022, an estimated $34K.
  • Denali Advisors first reported a position in Phathom Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Denali Advisors's Phathom Pharmaceuticals position peaked at $49K in Q4 2021.
  • 94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2022.

Based on Denali Advisors's 13F filing for Q2 2022, filed 18 Jul 2022.